Company Overview and News

94
5 Must-See Stock Charts for Wednesday — IBM Earnings Preview

3h investorplace
What a rebound in the stock market! The PowerShares QQQ ETF (NASDAQ:QQQ) surged 2.6%, the Dow Jones jumped almost 500 points and for once, small caps led the rally rather than the decline. That sets up a ton of must-see stock charts and top stock trades for tomorrow.
IBM GE QQQ GEC CGC ADBE BAC GS JPM WEED GNE MS DPZ SNAP

 
Domino’s Pizza Stock Drops on Disappointing Q3 Sales

2018-10-16 investorplace
Domino’s Pizza stock was down on Tuesday after releasing its earnings report for the third quarter of 2018.
DPZ

 
DPZ / Dominos Pizza Inc. 8-K (Current Report)

2018-10-16 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
DPZ

1
DPZ / Dominos Pizza Inc. 10-Q (Quarterly Report)

2018-10-16 sec.gov - 1
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION
DPZ

259
Stocks To Watch: Was That A Speed Bump?

2018-10-13 seekingalpha - 5
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
GLBS PERY PSX LCII ABT CRM SHPG CSCO MS AMC COF-P SMPL ISRG SYF DVMT IDA JNJ HON.WI MSFT HLUKF LEVL FTCH APHQF UTHR MTW ADS FB SCL NFLX AXP SKX SU BAC COF-D COF-C COF-F AAPL CCI ELAN HUBB CE SU EB SURF TRIP PVTL GSK EOG SIX JPM PATK SBUX CNTTF KMRFZ CNC CNK WMT NKE SHAK AMZN HON KMI TWTR HCSG GSK TRMB EAF KMR AA DXC CVB EBAY REGN SLB BAC DFS CRON STBA SC UAL GOOGL LTXB AHBIF PENN SCL SLB QCOM WFCNP XLNX PM PG PNK CPB PYPL VMW WGO TLRY USB GS MYL JEC SWI XYF WEED DXC.WI ECL ABT IBM CWH WFC HON BUD C TPR CMCSA THO COF BSVN LECO CGC SNY VLTHF V SCHW HP T MRK SNE DPZ

74
Cross-Currents In The Market - Cramer's Mad Money (10/8/18)

2018-10-09 seekingalpha
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, October 8.
VIA F TTWO NOW NFLX ORBC KMB ADBE AMZN PPG GOOGL SBUX DPZ DIS PZZA

23
Papa John’s Stock Ready to Serve Piping-Hot Profits?

2018-10-03 investorplace
Papa John’s International (NASDAQ:PZZA) stock investors have not had a great 2018 so far; however, people may still consider adding the company to their portfolio for the rest of the year. Specifically, there are three bullish plays in PZZA stock that I want to share with you, as each play could lead to impressive profits.
YUM DPZ MCD PZZA

88
10 Stocks to Sell in October

2018-09-27 investorplace - 1
With Halloween a little over a month away, both kids and adults are prepping for the fright-filled holiday. But since October also represents the start of the fourth quarter, it’s an ideal time to consider which stocks to sell.
WFCNP UAA NOV JWN NKE AAPL DIS WFC CMCSA TRIP UA TSLA QCOM DPZ PZZA

20
10 Stocks to Buy as the NFL Season Kicks Off

2018-08-31 investorplace
After a crowded sports year, which included the Winter Olympics and the World Cup, we’re finally back to what matters — the NFL. Americans love major sporting events, but none resonates more deeply than the National Football League. With the season opener mere days away, it’s time to consider stocks to buy that benefit from the NFL.
BUD UAA HIBB NFLX GOOG UA NKE PEP GOOGL AAPL DKS VZ KO MSFT DPZ PZZA

29
7 Best Restaurant Stocks to Bite Into Today

2018-08-30 investorplace
In this bull market, investors have clearly preferred growth stocks to value stocks. But they’ve been reasonably hot toward restaurant stocks, too.
YUM EAT YUMC BWLD PBPB CHUY QSR.WI SHAK HABT FRGI MSFT PLAY DIN ZOES QSR WING MCD DPZ PZZA

 
When sorry isn't enough — pressure grows on companies to apologize quickly in the age of viral content

2018-08-22 cbc.ca
Smartphones, social media, and the speed at which videos go viral are creating new pressures in boardrooms everywhere, whenever executives have to quickly handle a mess-up.
ACDVF DPUKY DPZ AC

17
Walmart Has Become A Must-Own Stock - Cramer's Mad Money (8/16/18)

2018-08-17 seekingalpha - 1
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, August 16.
GOOS ANGI COST WMT CRM SIRI MTCH ALXN AAPL AEP DPZ

50
10 Stocks to Buy on a Pullback | InvestorPlace

2018-08-16 investorplace - 3
Will this bull-run ever end? “Since we are back close to the highs for the S&P 500, risks of a pullback have certainly risen,” Wall Street veteran Bill Stone told CNBC recently.
SPLK HD TWLO DBX AMZN DATA ANGI COST DPZ

21
7 Alternative Consumer Stocks to Buy With 25% Upside

2018-08-15 investorplace
Consumer stocks are on fire so far in 2018 — the Consumer Discretionary Select SPDR ETF (NYSEARCA:XLY) is up 14% year to date through August 13, double the performance of the S&P 500 — and that’s got Goldman Sachs (NYSE:GS) singing the praises of 7 companies that include a hotel chain, food services business, a casino operator, and several more.
H BXG BBX DRI MDLZ SKX BETR GS BJRI SBUX ARMK HSY DPZ PZZA

92
Strong U.S. Consumer Spending Seen Boosting Q2 Retail Results

2018-08-14 seekingalpha - 1
In the U.S. retail landscape, the strength seen in consumer spending continued into the second quarter of 2018. In fact, analysts polled by Thomson Reuters are becoming more bullish on consumer spending, as retailers get ready to report their earnings for Q2 2018.
DFRG FRAN TXRH TIF NFLX PIR AMZN LULU WING MCD RRGB YUMC FRSH GME VSTO BKNG BJRI DAVE TRI SBUX LOCO PLAY URBN DPZ

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 25754A201